NextPoint Therapeutics
Business Services · Massachusetts, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
Labcentral 238 Main Cambridge Massachuse...Phone Number
(508) 204-1115Website
www.nextpointtx.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
2
1
2
1
1
About NextPoint Therapeutics
NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 axis, also known as B7-H7. Our innovative approach integrates foundational science with a defined clinical biomarker strategy to deliver a new class of monotherapies for patients who do not benefit from PD-1/L1 inhibitors. NextPoint is simultaneously advancing therapeutic approaches utilizing the unique upregulation of HHLA2 in cancer as an anchor for tumor-targeting therapeutic modalities. Our team of proven drug developers is working closely with our renowned scientific founders to launch a new world of precision immuno-oncology and beyond.Explore more
NextPoint Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is NextPoint Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if NextPoint Therapeutics had a recent Job posting/layoffs
NextPoint Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when NextPoint Therapeutics launches new products
Funding: Get notified immidiatlly once NextPoint Therapeutics has new funding data
Check if NextPoint Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at NextPoint Therapeutics
Earning: See what the market has to say on NextPoint Therapeutics recently announced quarterly report
Check out if NextPoint Therapeutics is spiking on competitors!
Recommended Actions
Reach out to Masked Content who joined NextPoint Therapeutics as Masked Content
Find more new buyers
Compare Similar Companies to NextPoint Therapeutics
Compare insights from companies similar to NextPoint Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
NextPoint Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
NextPoint Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about NextPoint Therapeutics.
NextPoint Therapeutics financials insights
Gather financial insights about NextPoint Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2023
Series B
$80M
2024
Series B
$42.5M
NextPoint Therapeutics Tech Stack
A closer look at the technologies used by NextPoint Therapeutics
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
Left Company
Executive Move
Executive Moves, Left Company
Person-Based
Person-Based
Funding
Funding
NextPoint Therapeutics News & Media
NextPoint Therapeutics to Highlight Antibody-Drug Conjugate (ADC) and T Cell Engager (TCE) Preclinical Findings Targeting Novel B7-H7 Pathway at AACR Annual Meeting
CAMBRIDGE, Mass.--(BUSINESS WIRE)--NextPoint Therapeutics, a clinical-stage biotechnology company launching a new world of precision therapeutics through its leading scientific work on the novel B7-H7 axis, today announced the company will present four posters highlighting its B7-H7-targeted oncology pipeline at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2025, to be held in Chicago, from April 25-30, 2025. NextPoint's presentations will showcase its advanced theNextPoint Therapeutics Announces Upcoming Poster Presentation on a B7-H7 Directed T Cell Engager Therapy at SITC2024
CAMBRIDGE, Mass.--(BUSINESS WIRE)--NextPoint Therapeutics, a clinical-stage biotechnology company developing a new class of precision immuno-oncology and tumor-directed therapeutics targeting the novel B7-H7 axis, today announced an upcoming poster presentation at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting, being held from November 6-10, 2024 in Houston, Texas. Building on its deep biological understanding of the B7-H7 axis, NextPoint has developed a series of B7-H7 targNextPoint Therapeutics Announces First-in-class T Cell Engager NPX372 As New Drug Candidate Targeting B7-H7 in Solid Tumors
CAMBRIDGE, Mass.--(BUSINESS WIRE)--NextPoint Therapeutics, a clinical-stage biotechnology company developing a new class of precision immuno-oncology and tumor-directed therapeutics targeting the novel B7-H7 axis, today has unveiled NPX372, a novel T cell engager. NPX372 further expands NextPoint’s multi-modal focus on the emerging B7-H7 axis in cancer therapy. B7-H7, also known as HHLA2, is an emerging immunomodulatory receptor upregulated in various solid tumor types, including colorectal carNextPoint Therapeutics Chief Executive Officer Ivan Cheung Named to the 2024 TIME100 Health List
CAMBRIDGE, Mass.--(BUSINESS WIRE)--NextPoint Therapeutics announced that Chief Executive Officer Ivan Cheung has been named to the 2024 TIME100 Health List
Read more news
Top Business Services Companies
Top companies in Australia by revenue
Frequently Asked Questions Regarding NextPoint Therapeutics
Sign Up For FreeTo access detailed company insights
NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 axis, also known as B7-H7. Our innovative approach integrates foundational science with a defined clinical biomarker strategy to deliver a new class of monotherapies for patients who do not benefit from PD-1/L1 inhibitors. NextPoint is simulta... Read More
